Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravitreal aflibercept in moderately severe to severe nonproliferative diabetic retinopathy
2016-002639-14Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in nonproliferative diabetic retinopathy (NPDR) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Proportion of patients with at least 2-step improvement in DRSS score at week 24. Started Nov 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
nonproliferative diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on 2016-002639-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002639-14.